NEW YORK CITY, NY / ACCESS Newswire / December 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PetMed Express, Inc. ("PetMed" or "the Company") (NASDAQ:PETS). Investors who purchased PetMed securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PETS.
PetMed Investigation Details
On June 10, 2025, PetMed issued a press release "announcing it is delaying the release of the Company’s fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process." On this news, PetMed’s stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025.
Then, on July 1, 2025, PetMed announced a delay in the filing of its Annual Report for its 2025 fiscal year, citing, among other things, an internal investigation into revenue recognition. On this news, PetMed’s stock price fell $0.05 per share, or 1.51%, to close at $3.27 per share on July 1, 2025.
Then, on November 12, 2025, PetMed disclosed that it was unable to timely file its quarterly report for the third quarter of 2025 "without unreasonable effort or expense." PetMed said that "the Company requires additional time to first complete and file with the SEC its Quarterly Report on Form 10-Q for the prior quarterly period ended June 30, 2025, which has been delayed due to the now-completed previously disclosed investigation by the Company’s Audit Committee." On this news, PetMed’s stock price fell $0.94 per share, or 32.41%, to close at $1.96 per share on November 13, 2025.
What’s Next for PetMed Investors?
If you are aware of any facts relating to this investigation or purchased PetMed securities, you can assist this investigation by visiting the firm’s site: bgandg.com/PETS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to PetMed Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for PetMed Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_471184625/2457/2025-12-17T11:01:21